Updated:
SV Health Investors
SV Health Investors: Kate Bingham and Paul LaViolette lead a $4.0B healthcare platform spanning therapeutics, medtech, and growth equity from London and...
SV Health Investors
SV Health Investors was formed and built its track record over a 30-year span, making it one of the oldest healthcare-dedicated asset managers in the US and UK. The firm is headquartered in London with a significant office in Boston, deploying capital across the US and Europe. Its founding lineage is not publicly detailed, but its current leadership includes Managing Partners Kate Bingham (Therapeutics) and Paul LaViolette (Medtech), who oversee distinct fund strategies. Historically, SV managed diversified, multi-sector healthcare funds. It now operates specialized vehicles: Therapeutics Funds that invest from early-stage to late-stage biotech, including a dedicated Dementia Discovery Fund; a Growth Fund for healthcare services, medical products and digital health companies; and a Medtech Convergence Fund aimed at novel devices and remote-monitoring technologies. The firm has exited 75 companies via IPO or M&A, including Alector, Insulet, and Ophthotech (now Iveric bio). It targets investments in North America and Europe, with a portfolio spanning biotechnology, medical devices, and healthcare services. SV fields more than 50 investment professionals and operating partners, supported by an advisory board for its Growth Fund. Recent portfolio activity includes Prilenia's clinical trial data donation to CHDI Foundation and Artios's first patient dosed in a Phase 2 POLKA study, both announced in May 2026. The firm's investor relations and communications team is led by Hannah Maunder from the London office. Unlike generalist private equity firms, SV Health Investors concentrates entirely on healthcare but extends across all stages — seed, venture, growth, buyout, PIPE, and recapitalization — within that single vertical. Its structure as a multi-fund, multi-team platform under one brand allows separate investment committees and domain experts to pursue biotechnology, medical devices, and services independently, insulating medtech decisions from therapeutics biases.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
71 Kingsway, London, WC2B 6ST, UK
Additional offices
Boston, MA, United States
Principals
Kate Bingham
Managing Partner, Therapeutics
Michael Balmuth
Managing Partner, Healthcare Growth
Tom Flynn
Managing Partner, Healthcare Growth
Paul LaViolette
Managing Partner, Medtech
Greg Madden
Managing Partner, Medtech, Healthcare Growth
Nikola Trbovic
Managing Partner, Therapeutics
Sector focus
Frequently asked questions
How is SV Health Investors structured across its investment strategies?
SV operates three dedicated verticals, each with its own investment team and fund structures. The Therapeutics group manages early- to late-stage biotech funds — including a Dementia Discovery Fund — while the Healthcare Growth team provides growth capital and liquidity to services, medical products, and digital health companies. The Medtech Convergence Fund focuses on novel medical devices and remote-monitoring technologies.
What stage of investment does SV Health Investors target?
The firm invests across the full company lifecycle. Its strategies span seed, start-up, expansion, growth equity, management buyout, PIPE, and recapitalization. The Therapeutics unit funds precision medicine from early discovery through late-stage development, while the Growth Fund typically enters at the expansion stage and beyond.
In which geographies does SV Health Investors deploy capital?
SV invests primarily in the United States and Europe, with offices in Boston and London. Its portfolio and exited investments reflect a transatlantic footprint — companies such as AeroCare Holdings and Insulet originated in the US, while firms like Convergence Pharmaceuticals and Solexa Ltd were based in Europe.
Who leads the investment decisions at SV Health Investors?
Managing Partners Kate Bingham and Laurence Barker co-lead the Therapeutics team, Michael Balmuth and Tom Flynn head Healthcare Growth, and Paul LaViolette and Greg Madden oversee Medtech and Healthcare Growth. Senior Partners such as Mike Ross and Eugene Hill also shape strategy across the platform.
Does SV Health Investors manage a dedicated dementia fund?
Yes. SV runs a standalone Dementia Discovery Fund (DDF) within its Therapeutics vertical. The DDF has its own Scientific Advisory Board of experts, including Maria Carrillo, Chief Science Officer of the Alzheimer's Association, and operates alongside the firm's broader biotech funds.
What is SV Health Investors' track record on exits?
The firm reports 75 IPOs and M&A exits over its history. Disclosed realized investments include Alector, Insulet, Ophthotech (now Iveric bio), Shire Pharmaceuticals, and Solexa Ltd — spanning biotech, medical devices, and specialty pharmaceuticals.
Does SV Health Investors participate in fund commitments or only direct deals?
SV manages dedicated funds across its three verticals and invests directly into companies. It does not market itself as a fund-of-funds, but its Growth Fund Advisory Board and operating-partner network suggest capital is deployed alongside co-investors directly into healthcare operating companies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: